Jonathan Krakoff is an Endocrinology/Metabolic physician. OpenAlex indexes 312 publications with 11,768 citations (h-index 57); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
4212 North 16th Street
Phoenix, AZ 85016
Telephone
602-200-5217Provider last certified this registry record 9 Mar 2026.
Clinical trials
- Cross Calibration of Two Dual Energy Densitometers and Comparison of Regional Adipose Tissue Measurements by iDXA and MRI
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Investigation of the Gut Microbiota in Regulating Nutrient Absorption in Humans
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- The Effects of Exenatide (Byetta ) on Energy Expenditure and Weight Loss in Nondiabetic Obese Subjects
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Insulet CorporationProgram year20241 payment
- Medtronic, Inc.Program year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
52.9%Insulin Analog28.1%Lantus Solostar56%Novolog Flexpen44%Part D<11 patientsGLP-1 receptor agonist24.8%Ozempic100%Part D<11 patientsHormonal (systemic)
28.9%l-Thyroxine19%Levothyroxine Sodium100%Part D<11 patientsSomatostatin Analog9.9%Sandostatin Lar Depot100%Part D<11 patientsNervous system
18.2%Opioid Agonist18.2%Oxycodone-Acetaminophen100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Bruce Bartholow Duncan
Universidade Federal do Rio Grande do Sul
Alireza Esteghamati
Tehran University of Medical Sciences
Paul Zimmet
Monash University
André Pascal Kengne
South African Medical Research Council
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”